Our Science
Our Science
Partnerships
Arvinas’ PROTAC Degraders Power Our Partnerships
Our PROTAC Discovery Engine has driven some of the industry’s most significant targeted protein degradation breakthroughs and led to our robust preclinical and clinical pipeline.
To expand the universe of druggable targets, we are working both on our own and with strategic partners, including leading drug companies, academic experts, and others, to broaden and further accelerate our clinical programs.
In addition to our disclosed partnerships, Arvinas has multiple undisclosed pipeline and platform collaborations to improve upon its protein degrader engine.
Learn About Our Current Partnerships
We are expanding the potential impact of PROTACs for patients with our current partners, Pfizer, Novartis, and Genentech.
Research License
In January 2018, Arvinas announced a research and collaboration license agreement with Pfizer Inc. for the discovery and development of drug candidates using Arvinas’ PROTAC Discovery Engine, which is designed to degrade key disease-causing proteins. The multi-year collaboration covers multiple disease targets across several therapeutic areas. Arvinas may receive up to $830 million in upfront and potential development and commercialization milestone payments in addition to tiered royalties.
In July 2021, Arvinas and Pfizer Inc. announced a global collaboration to develop and commercialize vepdegestrant, an investigational, oral, estrogen-receptor-targeting PROTAC degrader. In September 2025, Arvinas announced an agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant, with the goal of rapidly bringing it to patients if approved.
In May 2024, Arvinas out-licensed luxdegalutamide (ARV-766), now known as JSB462, its second generation PROTAC androgen receptor degrader for patients with prostate cancer, and sold its preclinical AR-V7 program, to Novartis AG. Arvinas received a one-time, upfront payment in the aggregate amount of $150 million and is eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory, and commercial milestones for luxdegalutamide being met, as well as tiered royalties based upon worldwide net sales of luxdegalutamide.
In November 2017, Arvinas and Genentech, a member of the Roche Group, expanded their multi-year strategic license agreement to encompass additional disease targets. The collaboration was originally formed in October 2015 to develop new therapeutics using Arvinas’ PROTAC Discovery Engine.
As part of the expansion, Arvinas is now eligible to receive more than $650 million in development and commercialization milestones as well as tiered royalties on sales of products. Genentech has the option to further expand the collaboration to include other disease targets for consideration.
Opportunities for New Partnerships
We are open to partnerships with commercial and academic partners that extend our PROTAC Discovery Engine, including:
- Targets of potential interest to Arvinas
- Addressing new or different disease areas
- Leveraging novel E3 ligases for incorporation into PROTACs
- Targets or E3 ligases with ligands with suboptimal affinity or without function
- Targets with nontraditional binding ligands
- Novel approaches to identifying chemical binders
- Platform collaborations
- Partnerships on Arvinas’ pipeline programs
Interested in Partnering with Arvinas?
